Viloxazine
Viloxazine is a selective norepinephrine reuptake inhibitor (NRI) and serotonin norepinephrine modulating agent (SNMA) that inhibits the norepinephrine transporter (NET) and also modulates multiple serotonin receptors (5-HT2B agonist, 5-HT2C antagonist), increasing prefrontal cortical norepinephrine and serotonin availability. It is approved for attention-deficit/hyperactivity disorder (ADHD) in pediatric and adult patients as a non-stimulant option. Originally developed as an antidepressant, its ADHD indication was established through later clinical trials.
分子量
237.2900 g/mol
LogP
1.50
TPSA
39.70 Ų
Lipinski 五规则
符合
Pharmacokinetics (PK)
Pharmacodynamics (PD)
二维结构
Cite this structure
Embed this structure
SMILES
CCOc1ccccc1OCC1CNCCO1
InChI
InChI=1S/C13H19NO3/c1-2-15-12-5-3-4-6-13(12)17-10-11-9-14-7-8-16-11/h3-6,11,14H,2,7-10H2,1H3
Molecular Formula
C13H19NO3
HBD / HBA
1 / 4
可旋转键数
5
重原子数
17
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
常见问题
Viloxazine is a selective norepinephrine reuptake inhibitor (NRI) and serotonin norepinephrine modulating agent (SNMA) that inhibits the norepinephrine transporter (NET) and also modulates multiple serotonin receptors (5-HT2B agonist, 5-HT2C antagonist), increasing prefrontal cortical norepinephrine and serotonin availability. It is approved for attention-deficit/hyperactivity disorder (ADHD) in pediatric and adult patients as a non-stimulant option. Originally developed as an antidepressant, its ADHD indication was established through later clinical trials.
Yes, Viloxazine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL306700. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5666. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="viloxazine"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/viloxazine/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/viloxazine/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/viloxazine/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="viloxazine"></drugfyi-drug>